Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters

Bayraktaroglu, T.; Boztepe, H.; Kapran, Y.; Tanakol, R.; Alagoel, F.

doi:10.1055/s-0029-1241205

Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters

Atıf İçin Kopyala

Bayraktaroglu T., Boztepe H., Kapran Y., Tanakol R., Alagoel F.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, cilt.118, sa.8, ss.537-543, 2010 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 118 Sayı: 8
Basım Tarihi: 2010
Doi Numarası: 10.1055/s-0029-1241205
Dergi Adı: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.537-543
İstanbul Üniversitesi Adresli: Evet

Özet

Context: The presence and the importance of FasL (FasL, APO-1L/CD95L) in papillary microcarcinoma lesions which are smaller than 1.5 cm of the thyroid is unclear.